-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On August 25, Pfizer/BioNTech jointly announced that it had submitted a rolling submission of the third dose of COMIRNATY (COVID-19 vaccine, mRNA) to the FDA for the supplementary license application (sBLA) for the enhanced injection of biological products
This sBLA data submission is based on data from a phase III clinical trial.
In subjects who had no evidence of SARS-CoV-2 infection within 1 month of the third dose of vaccine, COMIRNATY induced the production of powerful neutralizing antibodies against the wild-type strain
In addition, after the third dose, 99.
Pfizer and BioNTech plan to submit these data to peer-reviewed journals in the next few weeks and submit these data to the European Medicines Agency (EMA) and regulatory agencies in other countries and regions around the world
The third dose of COMIRNATY booster injection has not been widely used in the United States.